PMID- 33929386
OWN - NLM
STAT- MEDLINE
DCOM- 20220201
LR  - 20220201
IS  - 1533-4023 (Electronic)
IS  - 0160-2446 (Linking)
VI  - 78
IP  - 2
DP  - 2021 Aug 1
TI  - Adverse Events of Sacubitril/Valsartan: A Meta-analysis of Randomized Controlled 
      Trials.
PG  - 202-210
LID - 10.1097/FJC.0000000000001049 [doi]
AB  - This review aimed to summarize the adverse events (AEs) reported during the use 
      of sacubitril/valsartan versus angiotensin converting enzyme inhibitors 
      (ACEI)/angiotensin II receptor blocker (ARB). Studies containing safety outcomes 
      or AEs during the use of sacubitril/valsartan versus ACEI/ARB were retrieved from 
      the MEDLINE, Embase, and Cochrane Library databases and clinical trials. From the 
      selected studies, the pooled risk ratios with 95% confidence intervals of 
      dichotomous outcomes were assessed by a random or fixed effects model in our 
      meta-analysis. Fourteen studies involving 20,261 patients were included in this 
      review. No significant differences were found in total AEs between the 
      sacubitril/valsartan and ACEI/ARB groups. Compared with ACEI/ARB, 
      sacubitril/valsartan decreased the risk of death, discontinuation due to AEs, and 
      renal dysfunction, whereas it increased the risk of hypotension. Specifically, 
      sacubitril/valsartan decreased the risk of death compared with ACEI/ARB, whereas 
      it increased the risk of hypotension for patients with heart failure and 
      decreased the risk of discontinuation due to AEs in White patients. It also 
      increased the risk of dizziness in Asians and decreased the risk of hyperkalemia 
      and renal dysfunction, whereas it increased the risk of hypotension when the 
      study duration was >/=48 weeks. The available evidence showed that 
      sacubitril/valsartan was associated with fewer side effects than ACEI/ARB, except 
      for hypotension. Study duration, race, and patients with primary diseases 
      affected the AEs of sacubitril/valsartan.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Huang, Yun
AU  - Huang Y
AD  - Department of Pharmacy, Ningbo Medical Center Lihuili Hospital, Ningbo, China; 
      and.
FAU - Zhang, YuYu
AU  - Zhang Y
AD  - Department of Pharmacy, Ningbo Medical Center Lihuili Hospital, Ningbo, China; 
      and.
FAU - Ma, Lili
AU  - Ma L
AD  - Department of Pharmacy, Ningbo Medical Center Lihuili Hospital, Ningbo, China; 
      and.
FAU - Zhou, Hua
AU  - Zhou H
AD  - Department of Pharmacy, Ningbo Medical Center Lihuili Hospital, Ningbo, China; 
      and.
FAU - Fang, Chongbo
AU  - Fang C
AD  - Department of Pharmacy, Ningbo Medical Center Lihuili Hospital, Ningbo, China; 
      and.
FAU - Chen, Chaolin
AU  - Chen C
AD  - Department of Pharmacy, Traditional Chinese Medical Hospital of Zhuji, Shaoxing, 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Protease Inhibitors)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aminobutyrates/*adverse effects
MH  - Angiotensin II Type 1 Receptor Blockers/adverse effects/*therapeutic use
MH  - Biphenyl Compounds/*adverse effects
MH  - Drug Combinations
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology/mortality
MH  - Female
MH  - Heart Failure/diagnosis/*drug therapy/mortality/physiopathology
MH  - Humans
MH  - Hypotension/chemically induced/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Neprilysin/antagonists & inhibitors
MH  - Protease Inhibitors/*adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Risk Factors
MH  - Treatment Outcome
MH  - Valsartan/*adverse effects
MH  - Young Adult
COIS- The authors report no conflicts of interest.
EDAT- 2021/05/01 06:00
MHDA- 2022/02/02 06:00
CRDT- 2021/04/30 12:18
PHST- 2021/03/05 00:00 [received]
PHST- 2021/04/14 00:00 [accepted]
PHST- 2021/05/01 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
PHST- 2021/04/30 12:18 [entrez]
AID - 00005344-900000000-98251 [pii]
AID - 10.1097/FJC.0000000000001049 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2021 Aug 1;78(2):202-210. doi: 
      10.1097/FJC.0000000000001049.